Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- 7 January 2009
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 85 (5), 520-526
- https://doi.org/10.1038/clpt.2008.251
Abstract
Dapagliflozin selectively inhibits renal glucose reabsorption by inhibiting sodium-glucose cotransporter-2 (SGLT2). It was developed as an insulin-independent treatment approach for type 2 diabetes mellitus (T2DM). The safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug were evaluated in single-ascending-dose (SAD; 2.5-500 mg) and multiple-ascending-dose (MAD; 2.5-100 mg daily for 14 days) studies in healthy subjects. Dapagliflozin exhibited dose-proportional plasma concentrations with a half-life of approximately 17 h. The amount of glucosuria was also dose-dependent. Cumulative amounts of glucose excreted on day 1, relating to doses from 2.5-100 mg (MAD), ranged from 18 to 62 g; day 14 values were comparable to day 1 values, with no apparent changes in glycemic parameters. Doses of approximately 20-50 mg provided close-to-maximal SGLT2 inhibition for at least 24 h. Dapagliflozin demonstrates pharmacokinetic (PK) characteristics and dose-dependent glucosuria that are sustained over 24 h, which indicates that it is suitable for administration in once-daily doses and suggests that further investigation of its efficacy in T2DM patients is warranted.Keywords
This publication has 24 references indexed in Scilit:
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007
- First approved inhaled insulin therapy for diabetes mellitusExpert Opinion on Drug Delivery, 2006
- Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agentsExpert Opinion on Therapeutic Patents, 2005
- Type 2 diabetes mellitus: what is the optimal treatment regimen?American Journal Of Medicine, 2004
- Current Therapies and Emerging Targets for the Treatment of DiabetesCurrent Pharmaceutical Design, 2001
- Management of type 2 diabetes: a challenge for patient and physicianPatient Education and Counseling, 2000
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)Jama-Journal Of The American Medical Association, 1999
- Evaluations of Retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): A feasibility studyDiabetes Care, 1996
- Diabetes Complications: Why Is Glucose Potentially Toxic?Science, 1996
- Hyperglycemie and Microvascular and Macrovascular Disease in DiabetesDiabetes Care, 1995